Innate immunity in Alzheimer’s disease: the relevance of animal models?
Open accessThe DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
The mouse is one of the organisms most widely used as an animal model in biomedical research, due to the particular ease with which it can be handled and reproduced in laboratory. As a member of the mammalian class, mice share with humans many features regarding metabolic pathways, cell morphology and anatomy. However, important biological differences between mice and humans exist and must be taken into consideration when interpreting research results, to properly translate evidence from experimental studies into information that can be useful for human disease prevention and/or treatment. With respect to Alzheimer's disease (AD), much of the experimental information currently known about this disease has been gathered from studies using mainly mice as models. Therefore, it is notably important to fully characterise the differences between mice and humans regarding important aspects of the disease. It is now widely known that inflammation plays an important role in the development of AD, a role that is not only a response to the surrounding pathological environment, but rather seems to be strongly implicated in the aetiology of the disease as indicated by the genetic studies. This review highlights relevant differences in inflammation and in microglia, the innate immune cell of the brain, between mice and humans regarding genetics and morphology in normal ageing, and the relationship of microglia with AD-like pathology, the inflammatory profile, and cognition. We conclude that some noteworthy differences exist between mice and humans regarding microglial characteristics, in distribution, gene expression, and states of activation. This may have repercussions in the way that transgenic mice respond to, and influence, the AD-like pathology. However, despite these differences, human and mouse microglia also show similarities in morphology and behaviour, such that the mouse is a suitable model for studying the role of microglia, as long as these differences are taken into consideration when delineating new strategies to approach the study of neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“…observed, specially in areas adjacent to plaques Significant gliosis by 6 months, especially in areas around plaques Impairment in the Morris water maze at 12 months 5xFAD (Oakley et al. 2006) Amyloid deposition starts at 1.5 months and is particularly high in subiculum and deep cortical layers.”
BackgroundInfluentialHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 4×
“This indicates that a component of microglial activity is likely to be involved in the onset and/ or the progression of the pathological events (Harold et al. 2009; Lambert et al. 2009; Jones et al. 2010a; Guerreiro et al. 2012; Jonsson et al. 2012), as well as potential peripheral immune…”
InfluentialImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Identification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 6×
“2010) and differ from the other macrophage populations in having a distinct homeostatic signature leading to the expression of microglial-specific genes (Butovsky et al. 2014).”
BackgroundInfluentialTranscriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation
Xue, J., Schmidt, S. V., Sander, J., Draffehn, A., Krebs, W., Quester, I., De Nardo, D., Gohel, T. D., Emde, M., Schmidleithner, L., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.01.006 · Cited by 2,210 · cited 1×
“Studies on the macrophage transcriptome have pointed out that it is more accurate to consider macrophage activation as a spectrum, in which different transcriptional programmes operate in response to changes in the cellular environment (Xue et al. 2014).”
BackgroundKarran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 4×
“manner, and this has hampered the development of treatments for late-onset AD (Karran et al. 2011).”
BackgroundMethodInfluentialInitiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
A comparative encyclopedia of DNA elements in the mouse genome
Yue, F., Cheng, Y., Breschi, A., Vierstra, J., Wu, W., Ryba, T., Sandstrom, R., Ma, Z., Davis, C., Pope, B. D., et al. (2014) · Nature · doi:10.1038/nature13992 · Cited by 1,781 · cited 2×
“Although there is a relatively high degree of conservation, many mouse genes show different expression profiles compared to their human orthologues, and the level of divergence varies depending on tissue type (Yue et al. 2014).”
BackgroundPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 1×
“Other clinical trials of passive immunisation using humanized anti-amyloid antibodies bapineuzumab (Salloway et al. 2014) or solanezumab (Doody et al. 2014) have demonstrated no clear effect in improving cognitive function or slowing rate of decline in participants with established AD.”
BackgroundEnhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 3×
“Interestingly, the NFTs appear before the amyloid plaques as early as 3 months to be widely present at 6 months, and were more severe than in the parental line JNPL3 (Lewis et al. 2001).”
BackgroundJankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · cited 2×
“…in 10–16-month-old hemizygotes Reports of impaired spatial learning, working, memory and contextual fear conditioning at\6 months APPSwe/ PSEN1dE9 (Jankowsky et al. 2004) Ab deposits can be found by 6 months Abundant plaques in the hippocampus and cortex by 9 months Progressive increase in…”
BackgroundMicroglia in neurodegenerative disease
Perry, V. H., Nicoll, J. A. R., & Holmes, C. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.17 · Cited by 1,543 · cited 1×
“The consequence of repetitive systemic infections on microglia is that they become ‘‘primed’’ and thus more susceptible to activation (Perry et al. 2010; Perry and Holmes 2014), acquiring an innate memory (Netea et al. 2015).”
BackgroundSelf-citationMicroglial interactions with synapses are modulated by visual experience
Tremblay, M.-È., Lowery, R. L., & Majewska, A. K. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000527 · Cited by 1,542 · cited 2×
“…of the microenvironment by microglial processes (Hanisch and Kettenmann 2007) and their attraction to active rather than non-stimulated synapses implies that microglia might monitor the functional state of synapses leading to plastic changes in healthy adult brain (Tremblay et al. 2010).”
BackgroundMullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513 · cited 10×
“APP KM670/ 671NL (Swedish) Increased total Ab including production and secretion of Ab42 and Ab40 (Mullan et al. 1992) APOE Catabolism of triglyceride-rich lipoprotein constituents.”
BackgroundInfluentialAβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 3×
“A long-term clinical-neuropathological follow-up of the patients showed continued cognitive decline despite clearance in amyloid plaques in some patients (Holmes et al. 2008).”
BackgroundResultInfluentialSelf-citationHolcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386
(2001) · The Lancet · doi:10.1016/s0140-6736(00)03589-3 · Cited by 1,338
Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329 · cited 3×
“In these mice, microglia clustering around amyloid deposits are dysfunctional and incapable of clearing amyloid (Hickman et al. 2008), and thus, the authors propose that the reduction in Ab clearance may be due to changes in gene regulation.”
BackgroundInfluentialTimeTree: A public knowledge-base of divergence times among organisms
Hedges, S. B., Dudley, J., & Kumar, S. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl505 · Cited by 1,234
Systemic inflammation and disease progression in Alzheimer disease
Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., & Perry, V. H. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b6bb95 · Cited by 1,139 · cited 1×
“For example, clinical studies have shown that patients affected by a systemic infection decline more rapidly (Holmes et al. 2003, 2009), and it is now recognised that systemic inflammation is an important component of human neurodegenerative diseases (Holmes 2013).”
BackgroundMicroglial priming in neurodegenerative disease
Perry, V. H., & Holmes, C. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.38 · Cited by 1,127
Microglial cell origin and phenotypes in health and disease
Saijo, K., & Glass, C. K. (2011) · Nature Reviews Immunology · doi:10.1038/nri3086 · Cited by 1,100 · cited 1×
“This phenotype is mainly found in the presence of apoptotic cells and is characterised by the expression of IL10 and TGFb, inhibition of the production of pro-inflammatory cytokines, and increased expression of scavenger receptors (Saijo and Glass 2011).”
BackgroundGene-expression profile of the ageing brain in mice
Lee, C.-K., Weindruch, R., & Prolla, T. A. (2000) · Nature Genetics · doi:10.1038/77046 · Cited by 1,055
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986 · cited 9×
“Studies using positron emission tomography (PET) imaging to trace amyloid and microglial activation have demonstrated that, like APPPS1 mice, AD patients have a significant increase in both amyloid and microglial signals, with the microglial signal particularly elevated in the vicinity of the amyloid signal (Edison et…”
BackgroundInfluentialGur, R. C., Turetsky, B. I., Matsui, M., Yan, M., Bilker, W., Hughett, P., & Gur, R. E. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-10-04065.1999 · Cited by 909 · cited 1×
“In humans, the white matter represents 45–50% of total brain volume, while in the mouse, it accounts only for around 10% (Gur et al. 1999; Zhang and Sejnowski 2000).”
BackgroundMcGeer, P. L., Itagaki, S., Tago, H., & McGeer, E. G. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90696-3 · Cited by 836 · cited 2×
“Activated microglia tend to cluster around Ab plaques (Hefendehl et al. 2011), a phenomenon widely described in human AD (McGeer et al. 1987; Zotova et al. 2011, 2013; Serrano-Pozo et al. 2013) and also observed in other mouse models of AD-like pathology (Frautschy et al. 1998; Stalder et al. 1999).”
BackgroundWebster, S. J., Bachstetter, A. D., Nelson, P. T., Schmitt, F. A., & Van Eldik, L. J. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00088 · Cited by 755 · cited 1×
“As mentioned above, each of these mutations is known to cause a familial form of AD, and thus, as a result of the multiple combined mutations, APPPS1 mice show age-related amyloid plaque deposition (Holcomb et al. 1998) and cognitive impairment (Webster et al. 2014).”
BackgroundStreit, W. J., Braak, H., Xue, Q.-S., & Bechmann, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0556-6 · Cited by 727 · cited 8×
“It was demonstrated in PS19 mice that microglial activation precedes tangle formation (Yoshiyama et al. 2007), consistent with the previous observations of the presence of dystrophic microglia preceding the appearance of tau pathology in AD patients (Streit et al. 2009).”
BackgroundResultInfluentialCoupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia in the Adult Brain
Askew, K., Li, K., Olmos-Alonso, A., Garcia-Moreno, F., Liang, Y., Richardson, P., Tipton, T., Chapman, M. A., Riecken, K., Beccari, S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.041 · Cited by 726 · cited 1×
“Interestingly, a recent study exploring the density of microglial cells in white and grey matter found no changes associated with ageing in either mouse or human brains (Askew et al. 2017).”
BackgroundMicroglia: Dynamic Mediators of Synapse Development and Plasticity
Wu, Y., Dissing-Olesen, L., MacVicar, B. A., & Stevens, B. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.08.008 · Cited by 661 · cited 3×
“In the adult mouse brain, they remain dynamic cells surveying the microenvironment (Nimmerjahn et al. 2005) and participating in synaptic plasticity (Wu et al. 2015).”
BackgroundJones, L., Holmans, P. A., Hamshere, M. L., Harold, D., Moskvina, V., Ivanov, D., Pocklington, A., Abraham, R., Hollingworth, P., Sims, R., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013950 · Cited by 606
Microglia Are Essential to Masculinization of Brain and Behavior
Lenz, K. M., Nugent, B. M., Haliyur, R., & McCarthy, M. M. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1268-12.2013 · Cited by 526 · cited 2×
“Interestingly, recent studies reported sexual dimorphism in microglial behaviour in the developing neonatal brain (Lenz et al. 2013) and in pathological conditions (Mirza et al. 2015), potentially explaining the gender-associated susceptibility observed in some neurodevelopmental and…”
BackgroundGrabowski, T. J., Cho, H. S., Vonsattel, J. P. G., Rebeck, G. W., & Greenberg, S. M. (2001) · Annals of Neurology · doi:10.1002/ana.1009 · Cited by 523
Alzheimer neuropathologic alterations in aged cognitively normal subjects
Davis, D. G., Schmitt, F. A., Wekstein, D. R., & Markesbery, W. R. (1999) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199904000-00008 · Cited by 516 · cited 2×
“2008), corroborating the previous studies that pointed out the lack of association between amyloid pathology and severity of dementia (Davis et al. 1999; CFAS 2001; Engler et al. 2006; Minett et al. 2016).”
ResultEdison, P., Archer, H. A., Gerhard, A., Hinz, R., Pavese, N., Turkheimer, F. E., Hammers, A., Tai, Y. F., Fox, N., Kennedy, A., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.08.001 · Cited by 513 · cited 6×
“Studies using positron emission tomography (PET) imaging to trace amyloid and microglial activation have demonstrated that, like APPPS1 mice, AD patients have a significant increase in both amyloid and microglial signals, with the microglial signal particularly elevated in the vicinity of the amyloid signal (Edison et…”
BackgroundInfluentialAsuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506 · cited 2×
“Immunotherapy against tau in tau-based model of rodents (Chai et al. 2011) induced decreased NFT burden and restored cognitive function (Asuni et al. 2007; Boimel et al. 2010; Boutajangout et al. 2010; Chai et al. 2011).”
BackgroundCribbs, D. H., Berchtold, N. C., Perreau, V., Coleman, P. D., Rogers, J., Tenner, A. J., & Cotman, C. W. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-179 · Cited by 499 · cited 1×
“Interestingly, in humans, the changes in inflammatory genes were significantly higher when comparing young with aged individuals than when comparing non-demented aged subjects with AD subjects (Cribbs et al. 2012).”
BackgroundReactive Glia not only Associates with Plaques but also Parallels Tangles in Alzheimer’s Disease
Serrano-Pozo, A., Mielke, M. L., Gómez-Isla, T., Betensky, R. A., Growdon, J. H., Frosch, M. P., & Hyman, B. T. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.05.047 · Cited by 488
Mittelbronn, M., Dietz, K., Schluesener, H. J., & Meyermann, R. (2001) · Acta Neuropathologica · doi:10.1007/s004010000284 · Cited by 482
Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways
Miller, J. A., Horvath, S., & Geschwind, D. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914257107 · Cited by 480 · cited 3×
“Considering all of the above, it has been suggested that the microglial transcriptome might account for the main inter-species differences in the brain transcriptome (Miller et al. 2010).”
BackgroundKrabbe, G., Halle, A., Matyash, V., Rinnenthal, J. L., Eom, G. D., Bernhardt, U., Miller, K. R., Prokop, S., Kettenmann, H., & Heppner, F. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060921 · Cited by 478 · cited 4×
“These results are relevant in the light of the findings discussed in the previous section regarding microglial motility and phagocytic activity, that microglial motility in AD transgenic mice is decreased and this impairment is spatially correlated with the presence of amyloid plaques (Krabbe et al. 2013).”
BackgroundResultInfluentialKitazawa, M., Cheng, D., Tsukamoto, M. R., Koike, M. A., Wes, P. D., Vasilevko, V., Cribbs, D. H., & LaFerla, F. M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100620 · Cited by 473 · cited 2×
“2012), blocking IL1b signalling (Kitazawa et al. 2011), or inhibition of TNFa expression (Chavant et al.”
BackgroundAnimal Models of Alzheimer Disease
LaFerla, F. M., & Green, K. N. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006320 · Cited by 419
Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD.
(2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-27 · Cited by 393 · cited 4×
“These results were consistent with the expression profile that they detected in the brains of AD patients, which showed increased expression of TNFa, AG1, CHI3L1, and CHI3L2 (Colton et al. 2006).”
BackgroundResultInfluentialEvaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD
Bayer, A. J., Bullock, R., Jones, R. W., Wilkinson, D., Paterson, K. R., Jenkins, L., Millais, S. B., & Donoghue, S. (2005) · Neurology · doi:10.1212/01.wnl.0000148604.77591.67 · Cited by 356 · cited 8×
“Increased Ab42/Ab40 ratio; increased Ab42 (Jayadev et al. 2010) CD33 Transmembrane receptor expressed on myeloid cells (Hollingworth et al. 2011) M239I Moderate cortical atrophy; Numerous neurofibrillary tangles; Numerous senile plaques, especially in the amygdala.”
MethodInfluentialReview: Systemic inflammation andAlzheimer's disease
Holmes, C. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2012.01307.x · Cited by 356
Association of Microglia with Amyloid Plaques in Brains of APP23 Transgenic Mice
Stalder, M., Phinney, A., Probst, A., Sommer, B., Staufenbiel, M., & Jucker, M. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65423-5 · Cited by 345 · cited 2×
“2013) and also observed in other mouse models of AD-like pathology (Frautschy et al. 1998; Stalder et al. 1999).”
BackgroundYamanaka, M., Ishikawa, T., Griep, A., Axt, D., Kummer, M. P., & Heneka, M. T. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1569-12.2012 · Cited by 326 · cited 1×
“…in APPSwePSEN1dE9 mice, the induction of peroxisome proliferator-activated receptor (PPAR)c that activates microglia by suppressing inflammatory gene expression and enhancing phagocytosis resulted in a reduction of Ab in the hippocampus and improvement of cognitive functions (Yamanaka et al. 2012).”
BackgroundGene expression in human brain implicates sexually dimorphic pathways in autism spectrum disorders
Werling, D. M., Parikshak, N. N., & Geschwind, D. H. (2016) · Nature Communications · doi:10.1038/ncomms10717 · Cited by 296
The age-related attenuation in long-term potentiation is associated with microglial activation
Griffin, R., Nally, R., Nolan, Y., McCartney, Y., Linden, J., & Lynch, M. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04165.x · Cited by 282
Song, M., Jin, J., Lim, J.-E., Kou, J., Pattanayak, A., Rehman, J. A., Kim, H.-D., Tahara, K., Lalonde, R., & Fukuchi, K.-I. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-92 · Cited by 273 · cited 1×
“In APPswe/PS1dE9, AD mouse model with a mutation in the toll-like receptor (TLR)-4 gene (causing a loss of function of this protein) decreased microglial activation was observed, with increased Ab deposition and aggravation of the cognitive deficits (Song et al. 2011).”
BackgroundInflammatory components in human Alzheimer’s disease and after active amyloid-β42 immunization
Zotova, E., Bharambe, V., Cheaveau, M., Morgan, W., Holmes, C., Harris, S., Neal, J. W., Love, S., Nicoll, J. A. R., & Boche, D. (2013) · Brain · doi:10.1093/brain/awt210 · Cited by 272 · cited 1×
“Activated microglia tend to cluster around Ab plaques (Hefendehl et al. 2011), a phenomenon widely described in human AD (McGeer et al. 1987; Zotova et al. 2011, 2013; Serrano-Pozo et al. 2013) and also observed in other mouse models of AD-like pathology (Frautschy et al. 1998; Stalder et al. 1999).”
BackgroundSelf-citationAβ Species Removal After Aβ 42 Immunization
Nicoll, J. A. R., Barton, E., Boche, D., Neal, J. W., Ferrer, I., Thompson, P., Vlachouli, C., Wilkinson, D., Bayer, A., Games, D., et al. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000240466.10758.ce · Cited by 265
Self-citationJanelsins, M. C., Mastrangelo, M. A., Oddo, S., LaFerla, F. M., Federoff, H. J., & Bowers, W. J. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-23 · Cited by 260
Analysis of alternative splicing associated with aging and neurodegeneration in the human brain
Tollervey, J. R., Wang, Z., Hortobágyi, T., Witten, J. T., Zarnack, K., Kayikci, M., Clark, T. A., Schweitzer, A. C., Rot, G., Curk, T., et al. (2011) · Genome Research · doi:10.1101/gr.122226.111 · Cited by 252 · cited 2×
“They observed that the gene expression differences were more pronounced between young and aged people than between cognitively normal ageing and dementia (Tollervey et al. 2011).”
BackgroundDavies, D. S., Ma, J., Jegathees, T., & Goldsbury, C. (2017) · Brain Pathology · doi:10.1111/bpa.12456 · Cited by 251
Tau immunotherapy for Alzheimer's disease
Pedersen, J. T., & Sigurdsson, E. M. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.03.003 · Cited by 247 · cited 1×
“The first clinical trial of a phosphorylated tau immunogen has been completed regarding the safety, tolerability, and immunogenicity of the compound, and others trials are already underway (Pedersen and Sigurdsson 2015), but the findings have not been published yet.”
BackgroundCosenza;, M. A., Zhao;, M., Si;, Q., & Lee, S. C. (2002) · Brain Pathology · doi:10.1111/j.1750-3639.2002.tb00461.x · Cited by 238
Corneveaux, J. J., Myers, A. J., Allen, A. N., Pruzin, J. J., Ramirez, M., Engel, A., Nalls, M. A., Chen, K., Lee, W., Chewning, K., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq221 · Cited by 237
Wilcock, D. M., DiCarlo, G., Henderson, D., Jackson, J., Clarke, K., Ugen, K. E., Gordon, M. N., & Morgan, D. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-09-03745.2003 · Cited by 232 · cited 1×
“Anti-Ab immunisation was successful in decreasing amyloid plaque burden and this was facilitated by activated phagocytic microglia (Schenk et al. 1999; Wilcock et al. 2003, 2004a).”
BackgroundHart, A. D., Wyttenbach, A., Hugh Perry, V., & Teeling, J. L. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.11.006 · Cited by 230
Serrano-Pozo, A., Muzikansky, A., Gómez-Isla, T., Growdon, J. H., Betensky, R. A., Frosch, M. P., & Hyman, B. T. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182933788 · Cited by 226 · cited 1×
“Activated microglia tend to cluster around Ab plaques (Hefendehl et al. 2011), a phenomenon widely described in human AD (McGeer et al. 1987; Zotova et al. 2011, 2013; Serrano-Pozo et al. 2013) and also observed in other mouse models of AD-like pathology (Frautschy et al. 1998; Stalder et al. 1999).”
BackgroundMunoz, L., Ranaivo, H. R., Roy, S. M., Hu, W., Craft, J. M., McNamara, L. K., Chico, L. W., Van Eldik, L. J., & Watterson, D. M. (2007) · Journal of Neuroinflammation · doi:10.1186/1742-2094-4-21 · Cited by 224 · cited 1×
“Overall, high levels of pro-inflammatory cytokines have been related to cognitive impairment in various studies in both mice and humans (Munoz et al. 2007; Swardfager et al. 2010).”
Microglial immunophenotype in dementia with Alzheimer’s pathology
CFAS, M., Minett, T., Classey, J., Matthews, F. E., Fahrenhold, M., Taga, M., Brayne, C., Ince, P. G., Nicoll, J. A. R., & Boche, D. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0601-z · Cited by 219 · cited 16×
“It was also noted in this study that tangles were the only pathological feature related to cognition (Minett et al. 2016).”
BackgroundResultInfluentialSelf-citationWilcock, D. M., Munireddy, S. K., Rosenthal, A., Ugen, K. E., Gordon, M. N., & Morgan, D. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.09.015 · Cited by 202
Brendza, R. P., Bacskai, B. J., Cirrito, J. R., Simmons, K. A., Skoch, J. M., Klunk, W. E., Mathis, C. A., Bales, K. R., Paul, S. M., Hyman, B. T., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23269 · Cited by 190
β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease
Buttini, M., Masliah, E., Barbour, R., Grajeda, H., Motter, R., Johnson-Wood, K., Khan, K., Seubert, P., Freedman, S., Schenk, D., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1697-05.2005 · Cited by 176
Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice
Boimel, M., Grigoriadis, N., Lourbopoulos, A., Haber, E., Abramsky, O., & Rosenmann, H. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.05.010 · Cited by 174 · cited 4×
“Interestingly, one study did observe increased microglial activation (Boimel et al. 2010); whereas two other studies did not see changes in microgliosis (Boutajangout et al. 2010; Chai et al. 2011), possibly due to the different models and time-points examined (Chai et al. 2011).”
BackgroundResultInfluentialBiscaro, B., Lindvall, O., Tesco, G., Ekdahl, C. T., & Nitsch, R. M. (2012) · Neurodegenerative Diseases · doi:10.1159/000330363 · Cited by 164 · cited 2×
“Conversely, pharmacological inhibition of microglial activation, for example, with minocycline (Biscaro et al. 2012), blocking IL1b signalling (Kitazawa et al.”
BackgroundMizuno, T., Doi, Y., Mizoguchi, H., Jin, S., Noda, M., Sonobe, Y., Takeuchi, H., & Suzumura, A. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.06.011 · Cited by 159 · cited 2×
“For example, microglia express many markers that are typically associated with macrophages, such as CD11b (Roy et al. 2006), CD14 (Cosenza et al. 2002), CSF1R (colony-stimulating factor 1 receptor) (Mizuno et al. 2011), CD68, HLA-DR, MSR-A, and FccRI (Minett et al. 2016).”
BackgroundAmyloid-β Antibody Treatment Leads to Rapid Normalization of Plaque-Induced Neuritic Alterations
Lombardo, J. A., Stern, E. A., McLellan, M. E., Kajdasz, S. T., Hickey, G. A., Bacskai, B. J., & Hyman, B. T. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-34-10879.2003 · Cited by 149
Implication of the Immune System in Alzheimer's Disease: Evidence from Genome-Wide Pathway Analysis
Lambert, J.-C., Grenier-Boley, B., Chouraki, V., Heath, S., Zelenika, D., Fievet, N., Hannequin, D., Pasquier, F., Hanon, O., Brice, A., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100018 · Cited by 144 · cited 1×
“…among others have been identified as risk factors identified in case–control association studies or in GWAS, several occur in genes that are related to the immune response and inflammation (Harold et al. 2009; Lambert et al. 2010; Jones et al. 2010b; Guerreiro et al. 2012; Jonsson et al. 2012).”
BackgroundBaron, R., Babcock, A. A., Nemirovsky, A., Finsen, B., & Monsonego, A. (2014) · Aging Cell · doi:10.1111/acel.12210 · Cited by 118
Kawahara, K., Suenobu, M., Yoshida, A., Koga, K., Hyodo, A., Ohtsuka, H., Kuniyasu, A., Tamamaki, N., Sugimoto, Y., & Nakayama, H. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.01.049 · Cited by 113 · cited 1×
“Interestingly, treatment of APP23 mice with the anti-inflammatory cytokines IL4 and IL13 led to an amelioration of cognitive deficits (Kawahara et al. 2012).”
BackgroundMacrophages in Alzheimer’s disease: the blood-borne identity
Gate, D., Rezai-Zadeh, K., Jodry, D., Rentsendorj, A., & Town, T. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0422-7 · Cited by 107 · cited 1×
“Whether these cells may be relevant for the immune response in the brain and if their participation may be beneficial or detrimental in the disease pathogenesis is still unclear (Simard et al. 2006; Gate et al. 2010) and needs to be further studied in both humans and mice.”
BackgroundAlzheimer's disease: The forgetting gene
Spinney, L. (2014) · Nature · doi:10.1038/510026a · Cited by 98 · cited 1×
“Ageing and polymorphism of the apolipoprotein E (APOE) gene are the main risk factors for AD (McDowell 2001; Spinney 2014).”
BackgroundCognitive impairment in humanized APP×PS1 mice is linked to Aβ1–42 and NOX activation
Bruce-Keller, A. J., Gupta, S., Knight, A. G., Beckett, T. L., McMullen, J. M., Davis, P. R., Murphy, M. P., Van Eldik, L. J., St Clair, D., & Keller, J. N. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.07.012 · Cited by 96
Cited by
APP mouse models for Alzheimer’s disease preclinical studies.
Sasaguri, H., Nilsson, P., Hashimoto, S., Nagata, K., Saito, T., De Strooper, B., Hardy, J., Vassar, R., Winblad, B., & Saido, T. C. (2017) · The EMBO Journal · doi:10.15252/embj.201797397 · Cited by 793
Lopez‐Rodriguez, A. B., Hennessy, E., Murray, C. L., Nazmi, A., Delaney, H. J., Healy, D., Fagan, S. G., Rooney, M., Stewart, E., Lewis, A., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12341 · Cited by 293
Self-citationMicroglia and Astrocyte Function and Communication: What Do We Know in Humans?
Garland, E. F., Hartnell, I. J., & Boche, D. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824888 · Cited by 165
Self-citationLoss of IBA1-Expression in brains from individuals with obesity and hepatic dysfunction
Lier, J., Winter, K., Bleher, J., Grammig, J., Mueller, W. C., Streit, W., & Bechmann, I. (2019) · Brain Research · doi:10.1016/j.brainres.2019.01.006 · Cited by 26
Kim, J., Selvaraji, S., Kang, S. W., Lee, W. T., Chen, C. L.-H., Choi, H., Koo, E. H., Jo, D.-G., Leong Lim, K., Lim, Y.-A., et al. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.04.011 · Cited by 20
Metadata
- Authors
- Franco Bocanegra, D. K., Nicoll, J. A. R., & Boche, D.
- Venue
- Journal of Neural Transmission
- Published
- 2017-05-17
- Volume
- 125
- Issue
- 5
- Pages
- 827-846
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W2614951468
- Cited by
- 30
- References
- 80
- FWCI
- 1.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.